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Abstract
Objectives: We sought to evaluate the relation between atrial fibrillation (AF) and the extent of myocardial scarring together
with left ventricular (LV) and atrial parameters assessed by late gadolinium-enhancement (LGE) cardiovascular magnetic
resonance (CMR) in patients with hypertrophic cardiomyopathy (HCM).
Background: AF is the most common arrhythmia in HCM. Myocardial scarring is also identified frequently in HCM. However,
the impact of myocardial scarring assessed by LGE CMR on the presence of AF has not been evaluated yet.
Methods: 87 HCM patients underwent LGE CMR, echocardiography and regular ECG recordings. LV function, volumes,
myocardial thickness, left atrial (LA) volume and the extent of LGE, were assessed using CMR and correlated to AF. Additionally,
the presence of diastolic dysfunction and mitral regurgitation were obtained by echocardiography and also correlated to AF.
Results: Episodes of AF were documented in 37 patients (42%). Indexed LV volumes and mass were comparable between HCM
patients with and without AF. However, indexed LA volume was significantly higher in HCM patients with AF than in HCM
patients without AF (68 ± 24 ml·m-2 versus 46 ± 18 ml·m-2, p = 0.0002, respectively). The mean extent of LGE was higher in
HCM patients with AF than those without AF (12.4 ± 14.5% versus 6.0 ± 8.6%, p = 0.02). When adjusting for age, gender and
LV mass, LGE and indexed LA volume significantly correlated to AF (r = 0.34, p = 0.02 and r = 0.42, p < 0.001 respectively). By
echocardiographic examination, LV diastolic dysfunction was evident in 35 (40%) patients. Mitral regurgitation greater than II
was observed in 12 patients (14%). Multivariate analysis demonstrated that LA volume and presence of diastolic dysfunction
were the only independent determinant of AF in HCM patients (p = 0.006, p = 0.01 respectively). Receiver operating
characteristic curve analysis indicated good predictive performance of LA volume and LGE (AUC = 0.74 and 0.64 respectively)
with respect to AF.
Conclusion: HCM patients with AF display significantly more LGE than HCM patients without AF. However, the extent of LGE
is inferior to the LA size for predicting AF prevalence. LA dilation is the strongest determinant of AF in HCM patients, and is
related to the extent of LGE in the LV, irrespective of LV mass.
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Hypertrophic cardiomyopathy (HCM) is a complex and
relatively common form of genetic heart disease and the
most frequent cause of sudden death in the young [1].
HCM is macroscopically characterized by -often asymmet-
rical - left ventricular (LV) hypertrophy in the absence of
any systemic or cardiac disease likely to cause this hyper-
trophy. Histologically, myocyte disarray, scarring and
microvascular dysfunction are the hallmarks of HCM.
Atrial fibrillation (AF) is the most common arrhythmia in
HCM [2-5]. In general, AF is associated with unfavourable
prognosis secondary to an increased risk of heart failure-
related mortality, thrombo-embolism and severe func-
tional impairment [6-10]. In HCM patients, increased left
atrial (LA) size, advanced age and congestive heart failure
symptoms have been shown to be independent predictors
of the occurrence of AF [11]. However, the effect of myo-
cardial scarring on the presence of AF has not been evalu-
ated yet.
Cardiovascular magnetic resonance (CMR) has a high spa-
tial resolution, is considered the gold standard for in vivo
determination of left ventricular (LV) mass and volumes,
and enables precise quantification of wall thickness and
dimensions [12,13]. Additionally, late gadolinium-
enhanced (LGE) CMR allows visualization of myocardial
scarring in HCM patients [14,15].
Given the association between the extent of LGE with pro-
gressive LV dilation, ventricular arrhythmias and markers
of sudden death in HCM patients we hypothesized that
the extent of LGE might also be associated with the pres-
ence of AF [16-18]. Thus, we used CMR and echocardiog-
raphy to evaluate whether the extent of LGE, LV and LA
size, diastolic dysfunction and mitral regurgitation were
associated with AF in HCM patients.
Methods
Study population
In total, 102 consecutive HCM patients referred for CMR
were selected between February 2003 and December 2006
at 2 referral centers: 1st Department of Medicine, Univer-
sity Hospital of Mannheim, Germany and the Department
of Cardiology, VU University Medical Center, Amsterdam,
the Netherlands. All HCM patients were diagnosed based
on conventional criteria; left ventricular hypertrophy ≥ 15
mm on two-dimensional echocardiography in the
absence of another disease that could account for the
hypertrophy [19]. The work-up at intial diagnosis
included electrocardiogram (ECG), echocardiography,
coronary angiography, left ventriculography, 24-h Holter
ECG and CMR imaging. Every 6 months the majority of
patients underwent follow up visits including ECG,
echocardiography and 24-h Holter ECG. Of 102 HCM
patients, 15 patients were excluded due to concomitant
coronary artery disease (n = 4), previous myocardial inf-
arction (n = 3) or implantation of a pacemaker or defibril-
lator (n = 8), yielding a total of 87 patients included
finally in this study (54 males and 33 females; mean age
58 ± 13 years). This study was approved by the institu-
tional ethics committees of both participating medical
centers and informed consent was obtained from all sub-
jects.
CMR acquisition
All studies were performed using a 1.5 Tesla whole body
imaging system (Magnetom Sonata, Siemens Medical Sys-
tems, Erlangen, Germany). A dedicated four-element,
phased-array body coil was used. Images were acquired
during breath-holds in mild expiration. Scout images
(coronal, sagittal and axial planes) were obtained for
planning of the final double-oblique long-axis and short-
axis views. To evaluate functional parameters, ECG-gated
cine images were then acquired using a balanced seg-
mented steady state free precession (trueFISP) sequence.
Typical scan parameters were: 5 mm slice thickness with 5
mm interslice gap, temporal resolution 35 ms, repetition
time 3.2 ms, echo time 1.2 ms, flip angle 60 degrees, and
typical in-plane spatial resolution 1.4 × 1.8 mm2. After
obtaining standard 4, 3 and 2 chamber long axis cines, a
stack of 9 to 12 short-axis slices was used for full coverage
of the left and right ventricle. The LGE images were
obtained 10-15 min after intravenous administration of
0.2 mmol·kg-1 gadolinium-DTPA (Magnevist, Schering
AG, Berlin, Germany), using an inversion recovery turbo
Fast Low Angle Shot (FLASH) sequence with 6 mm slice
thickness at the same position as the long- and short-axis
cines in end diastole [20]. The inversion time was adjusted
per patient to optimally null signal from normal myocar-
dium typically between 250 and 300 ms. Total acquisition
time averaged 40 min.
Left ventricular and left atrial image analysis using CMR
LV end diastolic volumes, LV end-systolic volumes, LV
stroke volume, LV ejection fraction and LV myocardial
mass were assessed off-line from the serial short-axis true
FISP cine loops using dedicated commercially available
software (ARGUS, Siemens, Erlangen, Germany). In addi-
tion to volumetric measurements, one-dimensional meas-
urements of LV end diastolic dimensions (LVEDD),
posterior wall thickness (PWT) and maximum interven-
tricular septum wall thickness (SWT) were measured from
end diastolic short-axis views. LA volumes were measured
at end systole by the biplane area-length method on 4 and
2 chamber long axis views [21].
The extent of LGE was quantified using semi-automatic
commercially available software (MASS, Medis, Leiden,
the Netherlands) defining a signal intensity over 2 stand-Page 2 of 9
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of interest drawn in remote myocardium in the same slice
as where the LGE was present [14]. The extent of LGE was
then expressed as a percentage of the total LV mass to ena-
ble comparison of LGE burden between patients with dif-
ferent LV mass. LV and LA dimension and extent of LGE
were measured by 2 observers blinded to all clinical
patient details (TP; TG).
Echocardiography
Standard echocardiographic images were obtained using a
Vivid 7 machine (GE Ultrasound, Horton, Norway) with
a 2.5 MHz phased array transducer at end-expiratory
apnea.
Peak velocity of early (E) and late (A) wave of transmitral
flow and E-wave deceleration time (DT) were measured
from the pulsed-wave Doppler (PWD) obtained at the tip
of mitral leaflets. Tissue Doppler imaging (TDI) was used
to obtain early diastolic LV myocardial velocities (E') in
the apical 4- and 2-chamber views with a 2 mm sample
volume placed at the lateral, septal, anterior, and inferior
mitral annulus. The average of the four annular sites (E'glo-
bal) was used. All echocardiographic measurements were
averaged over three consecutive cardiac cycles, measured
by a single investigator blinded to all other variables. LV
diastolic dysfunction was defined as follows: [1] PWD cri-
teria: E/A ratio <1 if age <55 or <0.8 if age ≥ 55, and/or DT
>240 ms; [2] TDI criteria: E'global ≤ 12.9 cm/s if age <40;
E'global ≤ 10.2 cm/s if age 40-59; and E'global ≤ 7.2 cm/s if
age ≥ 60. Color Doppler flow imaging was used for semi-
quantitative assessment of mitral regurgitation.
Atrial Fibrillation
AF was documented based on ECG recordings obtained
when patients presented with acute onset of symptoms or
during follow up visits including 24 hour ambulatory
Holter ECG monitoring. AF was classified into paroxys-
mal and persistent. AF was considered paroxysmal when
self-terminating and persistent when sustained over 7
days. In our study only patients were included with epi-
sodes of atrial fibrillation of at least 1 hour.
Statistical Analysis
All data are presented as a mean ± standard deviation. For
comparing LV ejection fraction, LV end-systolic volume,
LA volume, LV mass, and percentage of LGE between
HCM patients with and without AF, an unpaired, 2-tailed
student's t-test was used. A Chi-square test was used to
evaluate if the presence of LGE and symptoms were differ-
ent between HCM patients with and without AF. To assess
differences in LV and LA dimensions and extent of LGE
between asymptomatic (NYHA I) and symptomatic HCM
patients (NYHA II-IV), an unpaired, 2-tailed student's t-
test was also used. Pearson's correlation was used to cor-
relate extent of LGE with LA volume and LV mass. Partial
correlation was used to correct the correlation between
the extent of LGE and LA volume with presence of AF for
age, gender and LV mass. Multivariate analysis was per-
formed with logistic regression analysis using block entry
of the following variables: LA volume, extent of LGE, LV
mass, presence of mitral regurgitation, presence of diasto-
lic dysfunction, age and gender to evaluate if these varia-
bles were independent predictors of AF, provided to have
a p < 0.10 in univariate analysis. Area-under-curve analy-
sis was performed to evaluate if LA volume, extent of LGE
and LV mass would increase the likelihood of having AF
in HCM patients. Additionally, receiver-operator-curve
analysis was used to determine the optional cut-off value
of LA volume and extent of LGE to discriminate patients
at increased risk of AF from patients without. All results
were considered statistically significant when p < 0.05.
Analyses were performed with Statistical Package for
Social Sciences (SPSS for windows 14.0, Chicago, IL,
USA).
Results
In 87 of included HCM patients, AF was documented in
37 HCM patients (43%) at time of initial diagnosis or dur-
ing follow-up. Baseline characteristics are presented in
table 1. AF was classified as paroxysmal in 27 patients
(31%) and persistent in 10 patients (12%). According to
the NYHA classification system, 41 (47%) were asympto-
matic (NYHA functional class I) and the other 46 (53%)
were symptomatic (NYHA functional classes II-IV). By
echocardiographic examination, LV diastolic dysfunction
was evident in 35 (40%) patients. Mitral regurgitation
greater than II was observed in 12 patients (14%). A total
of 45 patients (52%) were taking beta-blockers, 16 (18%)
calcium-channel blockers, 9 (10%) amiodarone, 3 (3%)
digitalis and 1 (1%) flecainide. A similar proportion of
patients in the AF and non AF subgroups were taking car-
dioactive medications.
Age, LV ejection fraction, LV end systolic volume, and LV
mass were all comparable between HCM patients with
and without AF. However, LV end systolic volume tended
to be larger and LV ejection fraction tended to be lower in
HCM patients with AF, see table 2. LA volume was signif-
icantly larger in HCM patients with AF than in patients
without AF (p = 0.0002). In symptomatic HCM patients,
LV end systolic volume (p = 0.04), LA volume (p = 0.03)
and extent of LGE (p = 0.03) were significantly larger com-
pared to asymptomatic HCM patients, see table 3. AF
occurred in 41% of asymptomatic HCM patients and in
43% of symptomatic HCM patients, which was not signif-
icant. In symptomatic patients the percentage of persistent
AF tended to be higher compared to asymptomatic
patients (17% versus 5%, p = 0.13).
In general, in our collective LGE occurred in a patchy dis-
tribution with multiple foci within hypertrophied regionsPage 3 of 9
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walls. In 14 patients LGE was limited at the RV insertion
points (16/59 = 27%). In two patients LGE was also
present in the lateral wall (2/59 = 3%). In 13 patients LGE
(13/59 = 22%) was diffuse trans-septal and RV septal. In
these patients, 10 had AF. However, the small sample size
precludes any firm conclusions.
The mean extent of LGE was higher in HCM patients with
AF compared to those without (12.4 ± 14.5% versus 6.0 ±
8.6%, p = 0.02). However, the prevalence of AF was com-
parable between HCM patients with LGE to those without
LGE (27/59, 46% versus 10/28, 35%, p = 0.5). When
adjusting for age, gender and LV mass, both the extent of
LGE and LA volume moderately correlated to AF (r = 0.34,
p = 0.02 and 0.42, p < 0.001 respectively). Interestingly,
LA volume moderately correlated to the extent of LGE (r =
0.31, p = 0.035), irrespective of LV mass, which did not
correlate with LA volume (r = 0.08, p = 0.69). LV mass also
did not correlate with the extent of LGE (r = 0.024, p =
0.83).
LA volume was significantly larger in HCM patients with
dystolic dysfunction than in patients without diastolic
Table 1: Patient Demographics and Baseline Characteristics.
All Patients (n = 87) Patients with AF (n = 37) Patients without AF (n = 50)
Age (years) 58 ± 13 59 ± 15 56 ± 11
Male gender 54 (61%) 22 (59%) 32 (64%)
Hypertension 8 (9%) 3(8%) 5(10%)
Diabetes mellitus 6 (7%) 3(8%) 3(6%)
NYHA functional class
I 41 (47%) 17(46%) 24(48%)
II 38 (44%) 16(43%) 22(44%)
III/IV 8 (9%) 4(10%) 4(8%)
Family history of HCM or sudden death 20 (23%) 9(24%) 11(22%)
Syncope 6 (7%) 4(10%) 2(4%)
Atrial fibrillation 37 (43%)
None 50(57%) 0 50(100%)
Paroxysmal 27(31%) 27 (73%) 0
Persistent 10(12%) 10 (27%) 0
Echocardiographic data
LV diastolic dysfunction, n (%) 35 (40%) 22 (59%) 13 (26%)
Mitral regurgitation
1 27 (31%) 15 (40%) 12 (24%)
≥ 2 12(14%) 7 (18%) 5 (10%)
Medications, n (%)
Beta-blocker 45(52%) 20 (55%) 25 (49%)
Calcium-channel blocker 16(18%) 7 (18%) 9 (18%)
Amiodarone 9(10%) 5(13%) 4 (8%)
Data are presented as the mean value ± SD or number (%) of subjects. NYHA = New York Heart Association; HCM = hypertrophic 
cardiomyopathy; LV = left ventricular
Table 2: LV and LA dimensions and extent of late gadolinium enhancement in HCM patients.
Atrial fibrillation (n = 37) No atrial fibrillation (n = 50) p-value
Age (years) 59 ± 15 56 ± 11 0.40
LV ejection fraction (%) 56 ± 10 61 ± 10 0.07
LV mass (gr·m-2) 97 ± 31 99 ± 34 0.76
LV EDD (mm) 51 ± 7 49 ± 8 0.51
SWT (mm) 19 ± 6 18 ± 4 0.28
PWT (mm) 10 ± 3 11 ± 3 0.28
LVEDV (mL·m-2) 86 ± 23 79 ± 20 0.16
LVESV (mL·m-2) 37 ± 14 31 ± 11 0.07
LVSV (mL·m-2) 49 ± 15 50 ± 15 0.89
LA volume (mL·m-2) 68 ± 24 46 ± 18 0.0002
LGE (%) 12.4 ± 14.5 6.0 ± 8.6 0.02
Data are presented as ± standard deviation. Volumes are indexed to body surface area. EDD = end diastolic dimension, EDV = end diastolic 
volume, ESV = end systolic volume, LA = left atrial, LGE = late gadolinium enhancement, LV= left ventricular, PWT = posterior wall thickness, SWT 
= septal wall thicknessPage 4 of 9
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dysfunction the mean extent of LGE tended to be higher
compared to HCM patients without diastolic dysfunction.
However, this comparison did not reach a significant level
(13% versus 9%, p = 0.3).
With multivariate logistic regression analysis, a model
using the extent of LGE, LA volume, presence of mitral
regurgitation and presence of diastolic dysfunction to pre-
dict AF in HCM patients had an r-square of 0.31, p < 0.01,
and revealed that only LA volume and diastolic dysfunc-
tion were independently associated with a history of AF in
HCM patients (p = 0.006, p = 0.01 respectively).
The univariate association between the presence of AF
with LA volume and extent of LGE was confirmed with
ROC analysis, see figure 1. The receiver-operator curve
indicates that cut-off value for LA volume of 49.8 ml/m2
has optimal discriminative power to predict AF, yielding a
sensitivity of 80.8% and specificity of 64.1%. With respect
to the extent of LGE, an optimal cut-off value of 3.3% was
found to have a sensitivity of 76.9% and a specificity of
59.0%, see figure 1.
Discussion
The present CMR study demonstrates that HCM patients
with AF had larger LA volumes and displayed more LGE
Table 3: Comparison of left ventricular and left atrial dimensions between asymptomatic and symptomatic HCM patients.
Asymptomatic HCM (n = 41) Symptomatic HCM (n = 46) p-value
Atrial fibrillation 17 (41%) 20(43%) 0.68
None 24(59%) 26(57%) 0.97
Paroxysmal 15(37%) 12(26%) 0.41
Persistent 2(5%) 8(17%) 0.13
LV ejection fraction (%) 60 ± 10 58 ± 9.5 0.32
LV mass (gr·m-2) 99 ± 30 97 ± 34 0.84
LV end systolic volume (ml·m-2) 29 ± 13 37 ± 13 0.04
LA volume (ml·m-2) 48 ± 21 59 ± 23 0.03
Extent of LGE (%) 6.0 ± 9.0 11 ± 13 0.03
Data are presented as ± standard deviation. Volumes are indexed to body surface area. HCM = hypertrophic cardiomyopathy patients, LA = left 
atrial. LGE = late gadolinium enhancement, LV = left ventricular
Receiver operating characteristic (ROC) curve analysis of left ventricular mass, extent of late gadolinium enhancement (LGE) area and left atr al volume as a predictor of AFFigure 1
Receiver operating characteristic (ROC) curve analysis of left ventricular mass, extent of late gadolinium 
enhancement (LGE) area and left atrial volume as a predictor of AF. In the panel A, mean area-under-curve with 
95% confidence intervals are presented. In the panel B, ROC curves are presented of extent of LGE and left atrial volume to 
determine optimal cut-off values. LA = left atrial, LV = left ventricular, LGE = late gadolinium enhancement.Page 5 of 9
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dysfunction were independently associated with a history
of AF in HCM patients. However, among these two
parameters LA volume was the strongest independent
determinant of AF. Additionally, LA volume moderately
correlated to the extent of LGE irrespective of LV mass.
Also, in symptomatic HCM patients in this study, LV end-
systolic volumes and LA volumes were larger and extent of
LGE was higher compared to asymptomatic HCM
patients, which is in line with previous reports [16,22].
Interestingly, paroxysmal AF did not seem to be more
prevalent in symptomatic HCM patients than asympto-
matic HCM patients, but persistent AF tended to have a
higher prevalence in symptomatic HCM patients com-
pared to asymptomatic HCM patients.
AF is a commonly reported complication of HCM
[2,4,8,10]. Established AF is uncommon in the young, but
in adults its prevalence can reach up to 30% [23]. Remark-
ably, the prevalence of AF in our study population was
higher than previously reported. This may in part be due
to the large number of follow-up visits, ECGs and 24
hours ambulatory Holter ECG recordings in the majority
of patients. Since AF is considered a key determinant of
HCM-related morbidity and mortality [7,10-12], the iden-
tification of predictors of AF is of paramount clinical
importance.
In a community-based HCM population, Olivotto et al.
found that the strongest predictor of AF was increased LA
volume, independent of age and functional NYHA func-
tional class [11]. In addition to LA volume, Losi et al.
reported that LA fractional shortening and age were inde-
pendent predictors for the development of AF in HCM
patients [23]. However, interpretation of these studies
may be difficult, while LA volume measurement may be
hindered by a poor acoustic window which is inherent to
echocardiography. By using CMR, we merely omitted
these limitations to measure LA volume, and confirmed
the importance of LA volume in relation to AF in HCM
patients. In this CMR study, a LA volume cut-off value of
50 ml·m-2 had an optimal discriminative power to predict
AF, yielding a sensitivity of 81% and a specificity of 64%.
This cut-off value is comparable with the results from Losi
et al, who found a cut-off value of 44 ml·m-2 determined
with echocardiography [23]. The strong relation between
LA dilation and AF in HCM patients may be explained by
the electrical and structural remodeling that occur in the
process of LA dilation, including shortening of the atrial
effective refractory period and local conduction delay
[24].
In addition, AF was associated with LGE in HCM patients.
However, not the presence but the extent was shown to be
indicative for AF. This is in line with the findings of a
necropsy study of HCM patients performed by Yamaji et
al [25], who found that the extent of LV fibrosis was sig-
nificantly higher in HCM patients with AF (24.4 ± 0.6%)
than without AF (17.6 ± 0.7%). The total fibrotic burden
in the LV found by Yamaji et al was higher compared to
our findings. This difference might be explained by the
fact that patients in this necropsy study died from progres-
sive HCM, which has been associated with an increased
fibrotic burden in comparison with milder forms of HCM
[16]. Moreover, systematic underestimation of fibrosis
quantification is an important limitation of LGE imaging,
by which only focal, but not diffuse areas of fibrosis can
be visualized and quantified. In addition, the LV must
remain in diastasis for at least 100 ms for optimal quality
of the LGE images. Therefore, in this study, only HCM
patients with AF who had acceptable rate control were
referred for CMR, which may have introduced a selection
bias into our analysis.
The underlying mechanisms relating LV LGE with AF are
unknown. The histological background of LGE in HCM
patients has been suggested to be myocardial scarring
and/or interstitial fibrosis [15]. Focal areas of myocardial
scarring have been related to ventricular arrhythmias, but
may also serve as anatomical substrates for AF [17,18].
Interstitial fibrosis is produced by fibroblasts that are acti-
vated by cardiotrophic mediators, such as angiotensin II.
Interstitial fibrosis together with impaired relaxation of
the cardiomyocyte through altered Ca2+-handling may
ultimately lead to diastolic dysfunction of the LV and sub-
sequent LA dilation and explain the relation between the
extent of LGE, LA dilation and subsequent AF [26,27].
This statement was supported by the moderate, but signif-
icant correlation between LGE and LA volume found in
this study. Additionally, patients with diastolic dysfunc-
tion revealed considerably more LGE than patients with-
out, indicating a potential relationship between LGE and
diastolic function.
In contrast to patients with hypertension and in normal
population [28,29], LV mass did not correlate to LA dila-
tion in these HCM patients, see figure 2. In HCM patients,
mitral regurgitation, originating from systolic anterior
motion of the mitral valve leaflet due to LV outflow tract
obstruction and increased interstitial fibrosis and myocar-
dial scarring also importantly attribute to increased LA
volume. However, no quantitative data evaluating the rel-
ative contribution of the extent of LGE, LV diastolic dys-
function and mitral regurgitation to LA dilation in HCM
patients are yet available.
Mitral regurgitation is very common in patients with
HCM. Also, in our study population mitral regurgitation
was present in 39 (45%) patients. However, mitral regur-
gitation was not a independent predictor of AF in HCM
patients. Similar to our results, Losi et al. found that mitralPage 6 of 9
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multivariate analysis [23].
Clinical implication
Should further studies confirm the pathogenic role of
fibrosis in diastolic dysfunction and subsequent LA dila-
tion in HCM, different treatment options aimed at stop-
ping or even reversing the process of fibrosis could gain
clinical importance. For example, angiotensin II blockade,
statins and aldosteron antagonists, have already been
demonstrated experimentally to cause regression of fibro-
sis, hypertrophy and disarray in animal HCM models [30-
32]. Moreover, the strong relation between LA dilation
and AF may justify to use LA size > 50 mL·m-2 determined
with CMR as an indication to aggressively search for the
presence of AF.
Limitations
For cine and LGE imaging, we used a gap of 5 and 4 mm
between slices for full coverage of the left ventricle,
thereby omitting 40 to 50% of total myocardium. This
may potentially have introduced inaccuracy of volume
and mass measurement; however, in a comparative study
performed by Hogan et al, contiguous acquisition of slices
and acquisition with 4 mm showed comparable accuracy
and yielded comparable volumes [33]. As mentioned pre-
viously, LGE imaging systemically underestimates total
burden of diffuse fibrosis, but a recent CMR study has
shown promising results to overcome this limitation [34].
In addition, the temporal resolution of CMR cine imaging
was not sufficient to adequately assessed LV diastolic dys-
function. Therefore we used the echocardiographic data to
evaluate the diastolic function.
In conclusion, HCM patients with a history of AF display
significantly more LGE than HCM patients without AF.
However, the extent of LGE is inferior to the LA size for
predicting AF prevalence. LA dilation is the strongest
determinant of AF in HCM patients, and is related to the
extent of LGE in the LV, irrespective of LV mass.
HCM patients with comparable left ventricular mass and different left atrial sizeFigure 2
HCM patients with comparable left ventricular mass and different left atrial size. A, C. End diastolic 4 chamber 
cine images. Note that the left atrium of the first patient (A) is smaller compared to the left atrium of the second patient (C), 
despite comparable LV mass. The end diastolic short axis LGE images (B, D) reveal that the first patient (B) has no LGE, while 
the second patient (D) has extensive LGE of the septum, as indicated by the white arrowheads.Page 7 of 9
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